The Case of the Migrating Vax
25th February 2022
It is now well-established that the spike protein factories created by the experimental mRNA treatment intended to mitigate the effects of infection with the Wuhan Coronavirus do not remain at the site where they are injected. It is not yet clear whether this is due to improperly administered injections — which might be entering blood vessels rather than remaining intramuscular — or if the migration occurs no matter whether the injection is intravenous or not.
A team of German pathologists asked BioNTech (Pfizer) for information about the components of the company’s “vaccine”. They didn’t get much of an answer to their questions, but there is some interesting analysis in the report below.